drb

DRB is a nucleoside analog that inhibits several carboxyl-terminal domain (CTD) kinases including casein kinase II (IC50 range of 4-10 μM)

DRB18 is a highly effective pan-class inhibitor of glucose transporter proteins (GLUT). It significantly modulates energy-related metabolism in A549 cells by inducing alterations in the abundance of metabolites associated with glucose-related pathways. DRB18 exerts its effects by promoting G1 S phase arrest, increasing oxidative stress, and prompting necrotic cell death, ultimately displaying notable anti-tumor activity [1].

Tetanus Toxin (830–844), a biologically active peptide and a tetanus toxin-derived peptide TT830–844 CD4+ T-cell epitope, exhibits promiscuity by binding to a wide spectrum of HLA–DRB molecules. Consequently, it is anticipated to elicit CD4+ T-cell responses across a broad segment of the human population.

Influenza Hemagglutinin is an HLA-DRB 0101-restricted epitope from influenza hemagglutinin (307-319).

Tetanus Toxin (830–844) TFA is a bioactive peptide. It acts as a CD4+ T cell epitope derived from tetanus toxin (TT830–844). This hybrid CD4+ T cell epitope binds to various HLA-DRB molecules, potentially activating CD4+ T cell responses in a broad population.